Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why ResMed Stock Tumbled by 5% Today

A looming threat from a very powerful rival could significantly dampen a key business for the company.

LLY : 904.97 (-0.13%)
RMD.AX : 35.205 (-2.88%)
RMD : 238.03 (-5.12%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 78.58 (+0.06%)
PFE : 29.75 (-0.27%)
MRK : 118.64 (+0.30%)
LLY : 904.97 (-0.13%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.6100 (+0.71%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
HRTS : 34.67 (+0.14%)
THNR : 27.38 (-0.07%)
OZEM : 28.15 (-0.60%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 115.97 (+0.23%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

LLY : 904.97 (-0.13%)
GS : 484.58 (-0.17%)
TERN : 10.21 (+6.02%)
VKTX : 64.45 (+2.40%)
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart...

BIIB : 197.59 (-0.31%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 115.97 (+0.23%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
BAYRY : 7.7900 (+2.23%)
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.

AAPL : 220.69 (+1.80%)
MSFT : 430.81 (-1.00%)
NVDA : 113.37 (-1.92%)
AMZN : 186.43 (-0.24%)
LLY : 904.97 (-0.13%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 904.97 (-0.13%)
PFE : 29.75 (-0.27%)
NVO : 132.06 (+0.05%)
TDOC : 9.09 (-0.22%)
AMZN : 186.43 (-0.24%)
NVDA : 113.37 (-1.92%)
SFIX : 4.14 (+0.98%)
VKTX : 64.45 (+2.40%)
ALT : 7.43 (-1.85%)
RHHBY : 39.6100 (+0.71%)
HIMS : 16.31 (+1.30%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 115.97 (+0.23%)
BIIB : 197.59 (-0.31%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar